434. Partial Heart Transplant for Congenital Heart Disease.
作者: Douglas M Overbey.;Berk Aykut.;John A Kucera.;Cathlyn K Medina.;Neeta J Sethi.;Piers C A Barker.;Erin V Shea.;Joseph W Turek.
来源: JAMA. 2025年334卷12期1077-1083页
Partial heart transplant, or living valve replacement, has the potential to advance surgical management of irreparable valvular disease by providing a viable option with capacity for growth.
436. A Fall Prevention Program Integrated in Primary Health Care for Older People in Rural China: The FAMILY Cluster Randomized Clinical Trial.
作者: Junyi Peng.;Pengpeng Ye.;Boya Nan.;Shichun Yan.;Zhifang Li.;Qian Li.;Ruilin Meng.;Yangchun Li.;Tianyou Hao.;Lan Zhang.;Dandan Peng.;Zijian Xu.;Yanni Wang.;Lei Si.;Minghui Yang.;Yao Yao.;Jing Zhang.;Wei Tian.;Yongchen Wang.;Rebecca Ivers.;Maoyi Tian.
来源: JAMA. 2025年334卷12期1068-1076页
With rapidly aging populations globally, there is a lack of evidence on effective fall prevention strategies among community-dwelling older people in resource-constrained areas.
437. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.
作者: .;Cheng Xu.;Xiao-Yu Liang.;Xin-Qiong Huang.;Feng Jin.;Kun-Yu Yang.;Guang-Yuan Hu.;Xiao-Dong Zhu.;Ying Wang.;Ying Huang.;Ning Zhang.;De-Sheng Hu.;Ling Guo.;Guo-Rong Zou.;Xiao-Zhong Chen.;Shao-Wen Xiao.;Jin-Gao Li.;Liang-Fang Shen.;Yuan-Yuan Li.;Jing Huang.;Guo-Xian Long.;Ling Li.;Luo Huang.;Long-Jiang She.;Yuan Wu.;Wei-Hua Zeng.;Meng-Yun Qiang.;Wei-Xin Liu.;Yong Su.;Ling-Long Tang.;Fang-Yun Xie.;Fei Han.;Li-Xia Lu.;Yan-Qun Xiang.;Yan-Ping Mao.;Wen-Fei Li.;Xu Liu.;Qi Yang.;Guan-Qun Zhou.;Rui Guo.;Pu-Yun Ouyang.;Xiao-Hui Wang.;Lei Chen.;Li-Ting Liu.;Li Lin.;Ji-Bin Li.;Ai-Hua Lin.;Hong-Yun Zhao.;Shu-Bin Hong.;Yu-Sheng Jie.;Hui-Ling Huang.;Xu-Hua Tang.;Yue-Can Zeng.;Jing-Ping Yun.;Sheng-Bing Zang.;Zi-Ming Du.;Zu-Lu Ye.;Li-Zhi Liu.;Li Tian.;Hao-Jiang Li.;Ying-Lin Peng.;Na Liu.;Ying-Qin Li.;Ye-Lin Liang.;Han-Miao Wei.;Yu-Pei Chen.;Yuan Zhang.;Xiao-Jing Du.;Jia-Wei Lv.;Ying Sun.;Jun Ma.
来源: JAMA. 2025年334卷11期973-983页
With the programmed cell death protein 1 (PD-1) blockade toripalimab, omitting highly toxic concurrent cisplatin may be feasible for nasopharyngeal carcinoma (NPC) without compromising survival.
|